3 assets in Bile Duct Adenocarcinoma

Therapeutic assets addressing Bile Duct Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Bile Duct Adenocarcinoma	Georgetown University	P3	BB (64)
Cobimetinib Bile Duct Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Bile Duct Adenocarcinoma	National Cancer Institute (NCI)	P2	CC (44)